SG135193A1 - Dosing schedule for erbb2 anticancer agents - Google Patents

Dosing schedule for erbb2 anticancer agents

Info

Publication number
SG135193A1
SG135193A1 SG200706063-5A SG2007060635A SG135193A1 SG 135193 A1 SG135193 A1 SG 135193A1 SG 2007060635 A SG2007060635 A SG 2007060635A SG 135193 A1 SG135193 A1 SG 135193A1
Authority
SG
Singapore
Prior art keywords
erbb2
mammal
directed
inhibitor
anticancer agents
Prior art date
Application number
SG200706063-5A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SG135193A1 publication Critical patent/SG135193A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200706063-5A 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents SG135193A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18

Publications (1)

Publication Number Publication Date
SG135193A1 true SG135193A1 (en) 2007-09-28

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200706063-5A SG135193A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Country Status (18)

Country Link
US (1) US20050119288A1 (pt)
EP (1) EP1658080A1 (pt)
JP (1) JP2007502807A (pt)
KR (2) KR20080014144A (pt)
CN (1) CN1838959A (pt)
AR (1) AR045268A1 (pt)
AU (1) AU2004264726A1 (pt)
BR (1) BRPI0413745A (pt)
CA (1) CA2536140A1 (pt)
CO (1) CO5670356A2 (pt)
IL (1) IL173127A0 (pt)
MX (1) MXPA06001989A (pt)
NO (1) NO20061252L (pt)
RU (1) RU2328287C2 (pt)
SG (1) SG135193A1 (pt)
TW (1) TW200522966A (pt)
WO (1) WO2005016347A1 (pt)
ZA (1) ZA200600517B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2472341C (en) 2002-02-01 2011-06-21 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
MXPA06001767A (es) * 2003-08-14 2006-05-12 Array Biopharma Inc Analogos de quinazolina como inhibidores de la tirosina quinasa receptora.
DE602004004553T2 (de) 2003-09-19 2007-10-25 Astrazeneca Ab Chinazolinderivate
DK1746999T3 (da) 2004-05-06 2012-01-23 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amider
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
EP1896030A1 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
CN102772358A (zh) * 2005-06-16 2012-11-14 美瑞德生物工程公司 药物组合物及其用途
JP2009502960A (ja) * 2005-07-27 2009-01-29 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
EP1962839A4 (en) * 2005-11-14 2010-08-25 Ariad Pharma Inc ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
CA2632194C (en) 2005-11-15 2012-01-03 Array Biopharma Inc. N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
EP2010911A4 (en) * 2006-03-31 2009-05-13 Massachusetts Inst Technology TREATMENT OF TUMORS EXPRESSING EGF MUTANT RECEPTORS
AU2007234379A1 (en) * 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
CN103330694A (zh) 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
WO2008124822A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Method of treating brain cancer
AU2008236994A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
WO2008124826A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating cancer
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2417148T3 (es) 2007-06-08 2013-08-06 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
US20100087459A1 (en) * 2008-08-26 2010-04-08 Leonid Metsger Forms of lapatinib compounds and processes for the preparation thereof
CN104447995A (zh) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
WO2015115635A1 (ja) 2014-01-31 2015-08-06 凸版印刷株式会社 生体分子解析キット及び生体分子解析方法
AU2016343817B2 (en) 2015-10-28 2021-05-27 Tva (Abc), Llc SSTR-targeted conjugates and particles and formulations thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1292591T3 (da) * 2000-06-22 2005-05-30 Pfizer Prod Inc Bicykliske derivater til behandling af abnorm cellevækst
GEP20063872B (en) * 2001-12-12 2006-07-10 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production
MXPA04004107A (es) * 2001-12-12 2004-07-23 Pfizer Prod Inc Moleculas pequenas para el tratamiento del crecimiento celular anormal.
AU2003291394B2 (en) * 2002-11-20 2009-06-25 Array Biopharma, Inc Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
KR20050085749A (ko) * 2002-12-18 2005-08-29 화이자 프로덕츠 인크. 비정상적 세포 성장의 치료를 위한 4-아닐리노 퀴나졸린유도체

Also Published As

Publication number Publication date
ZA200600517B (en) 2007-02-28
CA2536140A1 (en) 2005-02-24
CN1838959A (zh) 2006-09-27
RU2006102125A (ru) 2007-09-27
JP2007502807A (ja) 2007-02-15
NO20061252L (no) 2006-05-16
MXPA06001989A (es) 2006-05-17
IL173127A0 (en) 2006-06-11
BRPI0413745A (pt) 2006-10-24
AR045268A1 (es) 2005-10-19
EP1658080A1 (en) 2006-05-24
WO2005016347A1 (en) 2005-02-24
AU2004264726A1 (en) 2005-02-24
RU2328287C2 (ru) 2008-07-10
US20050119288A1 (en) 2005-06-02
KR20080014144A (ko) 2008-02-13
KR20060037447A (ko) 2006-05-03
TW200522966A (en) 2005-07-16
CO5670356A2 (es) 2006-08-31

Similar Documents

Publication Publication Date Title
SG135193A1 (en) Dosing schedule for erbb2 anticancer agents
MXPA05003501A (es) Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen.
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
GEP20033140B (en) Substituted Bicyclic Derivatives Useful as Anticancer Agents
AU2483000A (en) Treatment of asthma with mek inhibitors
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
WO2004068931A3 (en) Amphiregulin antibodies and their use to treat cancer and psoriasis
TW200639159A (en) Treatment of pain
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
SI1530469T1 (sl) Transdermalna odmerna oblika, ki obsega aktivno sredstvo in antagonist v obliki soli in v obliki proste baze
TR199900827T2 (xx) Siklooksigenaz-2 inhibit�rlerinin neoplazinin tedavisinde ve �nlenmesinde kullan�m�.
WO2004004661A3 (en) Boroproline compound combination therapy
HK1091481A1 (en) Therapeutic agents useful for treating pain
WO2005077082A3 (en) INHIBITING CAV3 ISOFORMS AND THE δ25B SPLICE VARIENTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
IL165259A0 (en) Compounds useful in the treatment of anthraxa and inhibiting lethal factor
MX2021010560A (es) Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
ZA202104960B (en) Methods of treating pain with a thiazoline anti-hyperalgesic
WO2001080813A3 (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
DE60325965D1 (de) Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
HK1085744A1 (en) Steroid compounds with anti-tumor activity